J Acquir Immune Defic Syndr by Delaney, Kevin P. et al.
Using a Multitest Algorithm to Improve the Positive Predictive 
Value of Rapid HIV Testing and Linkage to HIV Care in 
Nonclinical HIV Test Sites
Kevin P. Delaney, PhD, MPH*, Jacqueline Rurangirwa, MPH†, Shelley Facente, MPH‡, Teri 
Dowling, MA, MPH‡, Mike Janson, MPH†, Thomas Knoble, MSW‡, Annie Vu, MPH§, Yunyin 
W. Hu, MPH†, Peter R. Kerndt, MD, MPH†, Jan King, MD, MPH∥, and Susan Scheer, PhD, 
MPH§
*Division of HIV/AIDS Prevention, US Centers for Disease Control and Prevention, Atlanta, GA
†Division of HIV and STD Programs, Department of Public Health, County of Los Angeles, Los 
Angeles, CA
‡HIV Prevention Section, San Francisco Department of Public Health, San Francisco, CA
§HIV Epidemiology Section, San Francisco Department of Public Health, San Francisco, CA
∥Department of Public Health, County of Los Angeles, Los Angeles, CA
Abstract
Background—Use of a rapid HIV testing algorithm (RTA) in which all tests are conducted 
within one client appointment could eliminate off-site confirmatory testing and reduce the number 
of persons not receiving confirmed results.
Methods—An RTA was implemented in 9 sites in Los Angeles and San Francisco; results of 
testing at these sites were compared with 23 sites conducting rapid HIV testing with off-site 
confirmation. RTA clients with reactive results on more than 1 rapid test were considered HIV+ 
and immediately referred for HIV care. The positive predictive values (PPVs) of a single rapid 
HIV test and the RTA were calculated compared with laboratory-based confirmatory testing. A 
Poisson risk regression model was used to assess the effect of RTA on the proportion of HIV+ 
persons linked to HIV care within 90 days of a reactive rapid test.
Results—The PPV of the RTA was 100% compared with 86.4% for a single rapid test. The time 
between testing and receipt of RTA results was on average 8 days shorter than laboratory-based 
confirmatory testing. For risk groups other than men who had sex with men, the RTA increased 
the probability of being in care within 90 days compared with standard testing practice.
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Conclusions—The RTA increased the PPV of rapid testing to 100%, giving providers, clients, 
and HIV counselors timely information about a client’s HIV-positive serostatus. Use of RTA 
could reduce loss to follow-up between testing positive and confirmation and increase the 
proportion of HIV-infected persons receiving HIV care.
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INTRODUCTION
HIV testing in nonclinical settings, such as outreach or other sites that do not offer disease 
management or treatment services, has been shown to be effective at increasing the 
proportion of persons aware of their infection.1,2 In the United States, a single reactive rapid 
HIV test result is considered a “preliminary-positive” result.3 Although Centers for Disease 
Control and Prevention (CDC) and Health Resources and Services Administration (HRSA) 
recommend referral of eligible clients to HRSA-funded clinics after a preliminary-positive 
result4 to facilitate timely linkage to care, supplemental laboratory-based testing is 
recommended after a reactive rapid HIV test.3,5 When test sites use off-site laboratory 
testing to confirm a preliminary-positive result, clients must wait until their laboratory result 
is ready to get a definitive result. Although referral after a preliminary-positive result is 
permissible, many sites do not offer referrals until after supplemental laboratory test results 
confirm infection. HIV testing programs in nonclinical settings that do not offer immediate 
referrals have experienced difficulty convincing clients to provide venipuncture specimens 
for confirmatory testing6 and recontacting clients to deliver confirmatory test results and 
subsequently linking clients to medical care.1,2,6–9
CDC guidelines for HIV testing in nonclinical settings10 indicate that “if 2 or more sensitive 
and specific rapid HIV tests became available, one positive rapid test could be confirmed 
with a different rapid test,” and this was reiterated as an acceptable criteria for confirmation 
of diagnosis for Ryan White HIV/AIDS program eligibility by CDC and HRSA in 2013.4 
Since 2001, the Food and Drug Administration (FDA) has approved 8 rapid HIV tests for 
use in multitest algorithms11–13 to determine the presence of HIV antibodies. Therefore, 
alternatives to the current testing algorithm that uses multiple rapid tests, which have been 
used extensively in resource-limited settings,14–18 have been proposed for use in United 
States.19 To date, these alternatives have principally been used to increase the positive 
predictive value (PPV) of the rapid HIV screening test. However, same-day referral of those 
with reactive rapid test results may also improve the linkage to HIV medical care.6,19–21 A 
goal of the President’s National HIV/AIDS Strategy is to increase the proportion of all HIV-
infected clients successfully linked to HIV medical care within 90 days from 65% to 85% by 
2015.22
In this study, we evaluated the PPV of a rapid HIV testing algorithm (RTA) using 3 tests in 
nonclinical HIV counseling and testing (HCT) sites in Los Angeles (LA) and San Francisco, 
CA, and the impact of testing with the RTA on receipt of confirmed HIV test results and 
linkage to HIV medical care.
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A total of 32 agencies funded by the collaborating local public health departments in LA and 
San Francisco offered rapid HCT services before study initiation in August 2007. HCT sites 
included mobile units, storefronts, health clinics, community-based organizations, a 
methadone clinic, and county jail services. Four programs in LA and 5 programs in San 
Francisco were selected to implement an HIV RTA as their standard method of providing 
HCT services for an 18-month period (intervention sites) from August 2007 through March 
2009. The other 23 sites served as comparison sites. Clients testing confidentially or 
anonymously at both intervention and comparison sites were eligible to participate in the 
study. Anonymous testers could provide their name to convert to confidential testing at any 
point during the testing session; only those testing confidentially could be reported to the 
HIV surveillance system or referred for HIV medical care.
All persons tested for HIV between August 1, 2007, and February 28, 2009, at the 32 HCT 
sites in LA and San Francisco were included in this study. All HCT sites in both cities used 
the OraQuick Advance HIV-1/2 HIV antibody test (Orasure Technologies Inc., Bethlehem, 
PA) (OraQuick) as their rapid HIV screening test and confirmed an initial reactive test result 
with a Western blot or immunofluorescence assay. Therefore, we chose OraQuick as the 
initial screening HIV test in the RTA, so that test specificity would be consistent with the 
comparison sites. At the 9 sites offering an RTA, persons with a preliminary-positive 
OraQuick result had blood collected via venipuncture for both laboratory confirmation 
(using Western blot or immunofluorescence assay) and for testing with the Clearview 
Statpak HIV-1/2 antibody test (Alere Inc., Waltham, MA). If the Clearview test was 
negative, the Unigold HIV-1 Rapid test (Trinity BioTech, Bray, Ireland) was performed. If 
both the OraQuick and the Clearview tests were positive, the Unigold test was not used. 
Persons with reactive results on 2 rapid tests were considered HIV infected and received 
immediate counseling and referral to HIV care. Persons with negative results on both the 
supplemental rapid tests were considered HIV uninfected and informed of this result. At 
both intervention and comparison sites, anticoagulated whole-blood specimens (EDTA) 
were collected for laboratory confirmation of preliminary-positive rapid test results. Persons 
tested at comparison sites received this confirmatory result at their disclosure visit, typically 
scheduled for 1 week later. Additional details about the implementation of the RTA and 
protocols developed for this study have been described by Rurangirwa et al.23,24
Routinely collected data from 2 sources were used for our analysis. All persons seeking HIV 
testing at study sites provided information to the collaborating public health departments for 
reporting to CDC’s HIV testing evaluation program.23–25 Identifiers, including name, date 
of birth, test date, test identification number, site of test, and gender, which are collected and 
maintained in both San Francisco and LA before data are de-identified and summarized for 
CDC, were extracted from these testing databases and matched to the HIV/AIDS 
surveillance case registry, the Enhanced HIV/AIDS Reporting System (eHARS). Details of 
the matching procedure are included in the Supplemental Digital Content (available at http://
links.lww.com/QAI/A735). For all clients whose testing and eHARS information could be 
matched, HIV viral load (VL) results were extracted from the eHARS and added to the data 
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from the testing system. A VL test result after the date of testing was considered evidence of 
having been linked to HIV care.
Sample sizes for analyses involving each of our primary outcomes are provided in Figure 1. 
Using laboratory-based results as the gold standard, we calculated the PPV for both single 
rapid test and RTA. Receipt of confirmatory HIV test results was based on documentation in 
the testing database of a date of return for posttest counseling and referral for HIV medical 
care. For intervention sites, counselors coded this date as the date of receipt of RTA results, 
which was the same day as the date of testing. Time to care was calculated as the time from 
the date of HIV test in the testing database to the date of the first VL result reported in the 
HIV surveillance registry.
Covariates from the testing database that might affect time to care were included in this 
analysis. These included race and ethnicity, HIV behavioral risk group (California’s coding 
of presumed mode of exposure to HIV), receipt of posttest counseling and referral to care, 
homeless status, and HIV testing history (both self-report of previous positive test results 
and receipt of their most recent previous test result). Unadjusted risk ratios26 were calculated 
to quantify associations between these characteristics and linkage to care within 90 days of 
their HIV test date.
Kaplan–Meier product limit survival curves, representing the cumulative probability of care 
over time, based on reported VL, were calculated using standard methods.27 Differences in 
cumulative probabilities between strata of covariates were assessed using the log rank test.27
The probability of being linked to care within 90 days of the HIV test date was modeled 
using a Poisson risk model28 that accounted for effects of testing site through the use of a 
random effect. To investigate whether the process of RTA (both testing and associated 
same-day posttest counseling) could affect the probability of being linked to care within 90 
days directly or only indirectly through increasing the likelihood of receipt of confirmed 
HIV test results and a referral for HIV care, we compared the results of 4 related models:
• Models 1 and 2 contained the independent variable of primary interest (RTA vs. 
not) and the outcome, time to care, without an additional measure of receipt of 
confirmed results and referral; additionally, model 2 included the same variables as 
model 1 and allowed for effect modification by HIV testing history and behavioral 
risk group.
• Model 3 was identical to model 2, except that it contained the measure of receipt of 
confirmed results and referral, and not the variable indicating RTA vs. not 
(reported in Table S1, see Supplemental Digital Content, http://
links.lww.com/QAI/A735).
• Model 4 contained both the variable indicating RTA vs. not and the variable 
measuring receipt of confirmed results and referral.
For each of these models, we calculated the ratios of the probability of being in care for 
those who were tested by RTA vs. received a rapid HIV test with off-site confirmatory 
testing while controlling for factors associated with time to care (for more discussion of the 
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modeling strategy, see Figure S1, Supplemental Digital Content, http://links.lww.com/QAI/
A735). We also assessed the possibility of effect modification by other covariates29–31 and 
report these results.32,33
All analyses were conducted using SAS software version 9.2 (SAS Institute, Cary, NC). 
This study was funded by the CDC under cooperative agreement PS06-002 and reviewed 
and monitored by the Institutional Review Boards at the CDC, the University of California 
San Francisco, and LA County Department of Public Health. All clients seeking HIV testing 
in study sites consented to HIV testing with either RTA or standard testing algorithm, and 
separate research consent was waived by the IRB under 45 CFR 46.116(d).
RESULTS
Between August 1, 2007, and February 28, 2009, a total of 59,299 HIV tests were performed 
at the 32 participating HCT sites (Fig. 1). Selected characteristics of the study population are 
included in Table 1. Most (71%) tests at both intervention and comparison sites were 
conducted in LA; however, proportionately more intervention site participants were 
recruited in San Francisco (41% vs. 24%). Participants receiving the intervention were also 
more likely than those who did not receive the intervention to be white, to have tested for 
HIV previously, and to have reported being a men who had sex with men (MSM) as their 
main HIV risk. There were no differences in the proportions that tested anonymously at 
intervention vs. comparison sites.
Table 2 describes the RTA results and the conventional testing results for 1165 clients with a 
preliminary-positive rapid test. Most of these tests occurred at comparison sites (79%), but 
the false-positive rates were similar at intervention and comparison sites. By design, all 
clients at the intervention sites with a preliminary-positive rapid test received results of 
additional rapid tests performed on site in the same visit and therefore also received same-
day referral to HIV care. All 213 clients with positive results on 2 rapid tests were confirmed 
positive by the laboratory algorithm (PPV = 100%); likewise, 37 clients with false-positive 
OraQuick results were negative by both the laboratory algorithm and the RTA.
The PPV of the single rapid test at the comparison sites was 86.4%. More than half (53%) of 
the clients at comparison sites failed to return for laboratory-based confirmatory test results, 
including 76 clients with false-positive and 409 with confirmed positive results. For clients 
tested at comparison sites to receive the results of their laboratory-based confirmatory test 
took an average of 8 days (range, 1–137 d).
Of the 1004 persons determined to be HIV infected, 775 could be linked to the eHARS data 
registry (Fig. 1). Of these, 179 (23%) tested at intervention sites. Overall, there was a shorter 
time (statistically nonsignificant) from testing to first laboratory evidence of linkage to HIV 
care among those tested at the intervention sites, compared with those tested at the 
comparison sites (Fig. 2A). Clients who received their test results and referral, either by 
returning for confirmatory results at a comparison site or by testing at an intervention site, 
had a significantly shorter time from HIV test result to HIV care compared with those who 
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did not come back to receive their laboratory-based confirmatory results and therefore did 
not receive a referral to HIV care (Fig. 2B).
Table 3 summarizes results of 3 mixed-effects Poisson risk regression models (models 1, 2, 
and 4, see Methods) assessing factors associated with linkage to HIV care within 90 days of 
HIV testing. Being tested at an intervention site with the RTA was not significantly 
associated with linkage to HIV care within 90 days after testing positive in either the 
unadjusted model (relative risk = 1.04, 95% confidence interval: 0.91 to 1.19) or model 1 
that adjusted for other factors associated with linkage to care (relative risk = 1.09; 95% 
confidence interval: 0.98 to 1.23). However, the unadjusted risk ratios suggested significant 
variation in the effect of RTA by risk group (MSM vs. other) and a previous HIV-positive 
test result. In a model that allowed for different RTA effects in different levels of these 2 
covariates (Table 3, model 2), the RTA had a significant effect on linkage to care for non-
MSM (for further description of the modification of the effect of RTA by risk group, see 
Table S2 and Figure S2, Supplemental Digital Content, http://links.lww.com/QAI/A735). In 
model 4 (Table 3), which also controlled for the effect of receiving posttest counseling and 
referral, the effect of the RTA was reduced and of similar magnitude to the effect of 
receiving posttest counseling and referral in a model that did not control for exposure to 
RTA (see Table S1, model 3, Supplemental Digital Content, http://links.lww.com/QAI/
A735). All models included a random intercept term for test site, representing the variation 
in baseline probability of linking clients to care within 90 days for each site. Heterogeneity 
in the baseline probability of linkage to care was spread across both intervention and 
comparison sites but was reduced significantly when receipt of results and referral were 
accounted for in the main effects of the models, such that the random effect term was not 
significant in model 3 (see Table S1, Supplemental Digital Content, http://
links.lww.com/QAI/A735) or 4 (Table 3).
DISCUSSION
Our study found that adding a second rapid test to confirm a preliminary-positive rapid test 
had significant advantages compared with use of a single rapid test confirmed by standard 
laboratory testing. First, the predictive value of the rapid test algorithm was 100% compared 
with 86.4% for the single rapid test. Furthermore, being tested at an RTA site allowed for 
same-day receipt of a confirmed test result4 and referral to care compared with sites offering 
standard laboratory confirmation, where less than half returned for confirmatory results and 
it took an average of 8 days between testing and return of these results with referral to HIV 
care. And, for non-MSM, being tested at an RTA site increased the probability of being in 
care within 90 days compared with standard testing practice.
Assuming independence and that the reported specificities11–13,34 for each test are accurate, 
we would expect a false-positive rapid test algorithm result to occur only once in every 
500,000 HIV tests of uninfected individuals. Although a prospective study large enough to 
confirm this is cost prohibitive, the only other large-scale evaluation of the RTA in the 
United States reported one false-positive result in 51,413 tests.20 Modeling35 based on 
studies in which all rapid tests were performed on the same individuals11 suggests that 
although complete independence cannot be assumed, the number of specimens with 
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concordant false-positive results on 2 different rapid HIV tests is less than 1/5000 for all 
possible combinations of FDA-approved rapid tests. In the present study, using an algorithm 
with tests with relatively lower individual specificity among the FDA-approved rapid 
tests11–13,34–37 suggests that it is even lower than this value. The excellent performance of 
FDA-approved tests in multitest algorithms had been anticipated based on extensive use of 
this strategy in developing countries where it is used routinely even in high-prevalence 
settings to improve the predictive value of rapid HIV testing.14–18 If study sites had referred 
all clients with a single reactive rapid test to HIV care, 161 such clients who were 
determined to be uninfected would have required at least one follow-up visit with the HIV 
care provider to figure out that they were uninfected. The ability to increase the predictive 
value of HIV testing at the point of contact is one key advantage of a rapid test algorithm, 
allowing both clients and counselors to have sufficient confidence in the test results to move 
to same-day HIV care referral.
This same-day referral seems to be the main advantage of the rapid test algorithm. Receiving 
confirmed results (whether via the RTA or not) during posttest counseling and referral was 
the strongest predictor of laboratory evidence of linkage to HIV care within 90 days of 
testing, with a 35% increase in the probability of being linked to care for those who received 
a referral compared with those who did not (Table 3, model 4). Because clients who 
received the RTA received a referral during the same visit, most of the effect of the RTA on 
linkage to care within 90 days of testing resulted from the same-day receipt of a referral. 
However, there seems to be some additional benefit to the RTA particularly for risk groups 
(injecting drug users and high-risk heterosexuals) who have previously been reported to 
have difficulty in successfully linking to HIV care.38–40 This result is surprising as the RTA 
in our study was not coupled with any other interventions41–48 that have already been shown 
to improve linkage to HIV care. Future studies could combine the RTA with initiation of 
one or more of these linkage interventions at the first visit to maximize the impact of testing 
on linkage to care48 to meet the objectives of the National HIV/AIDS Strategy.22
In our study, MSM not tested with the RTA were more likely (59.2% vs. 55.9%) to be 
linked to care within 90 days than MSM tested with the RTA. In contrast, we found that 
RTA testing clients in other risk groups were more likely to be in care within 90 days of 
their HIV test. We attempted to control for differences in underlying client characteristics 
(eg, drug use, poverty, health insurance status) and site characteristics (eg, experience of 
counselors, established linkages between testing sites and clinical care sites) by including an 
effect for random variation by study site, assuming that clients testing at a particular site 
were similar on these unmeasured potential confounders of our effect of interest. However, 
there were a small number (n = 43) of non-MSM tested via RTA, and reasons for their 
higher rate of linkage to care within 90 days could not be explored further in this analysis. It 
is possible that including a random effect variable for site did not adequately account for 
within-site differences in linkage to care across risk behavior groups, particularly for RTA 
sites that served primarily MSM populations.
The study has several limitations, including the lack of a randomized design. We were 
unable to randomize intervention or comparison sites because of the need for existing staff 
capacity and experience conducting rapid testing and limited resources with which to 
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implement a research protocol with a large number of sites with a small volume of tests 
performed annually. Although we attempted to control for factors that might contribute to 
both testing at an intervention site and linkage to HIV care, multivariate models that 
included effects for individual sites and even study area (LA and San Francisco) did not 
converge, likely because of the small number of HIV-infected persons tested with the RTA 
(n = 179) for whom linkage data were available (data not shown). The small sample size and 
possibility of residual confounding make separation of the effect of RTA into effects due to 
receipt of referral and other direct effects on linkage to care unwise.49 Furthermore, even if 
it is true that most of the effect of RTA on linkage to care was because of an increase in the 
number of clients who received confirmed results and a referral, we did not assess whether 
immediate referral to care after a single rapid test could have a similar impact on our 
outcome measure or what the impact of referral of persons who would ultimately be 
determined to be uninfected (161 persons with a false-positive rapid test in our study) might 
be. Nevertheless, having a comparison group and controlling for factors that might affect 
both receiving the RTA and accessing HIV care are improvements over previously reported 
evaluations of the RTA.20
The outcomes considered in this study (PPV, receipt of results, and linkage to HIV care 
within 90 d of testing) do not evaluate the relative sensitivity of rapid testing compared with 
laboratory testing. In high-incidence settings, false-negative rapid tests may occur and other 
testing methods may be preferred.50–52 However, data suggest that although laboratory-
based confirmatory testing may exhibit high sensitivity required to reduce the possibility of 
false-negative results, delays inherent in these testing methods still lead to loss to follow-up 
and delays in receipt of test results and referral to HIV care.53,54 The “realized sensitivity” 
of laboratory testing, in terms of number of persons who receive timely diagnosis of their 
HIV infection and linkage to HIV care, will be lower than that of currently available rapid 
tests if these clients are lost to follow-up without receiving their test results. Newly approved 
rapid tests,10,11 including one that detects HIV-1 antigen directly,11 have been reported by 
some55,56 but not all52 to be more sensitive than the tests used in this study, and their 
evaluation in RTA in a setting with high HIV incidence is warranted.
For analyses with time to evidence of linkage to HIV care and probability of being linked to 
care within 90 days as the outcomes of interest, we are limited by the completeness of 
surveillance reporting of HIV laboratory results. Since July 2002, licensed laboratories in 
California have been required to report all HIV VL test results to the local health 
department. Evaluations of the HIV/AIDS surveillance system have found that the reporting 
of laboratory results for HIV/AIDS cases was over 95% complete.57–59 Although it is 
possible that our estimates of both time to care and the proportion in care within 90 days 
may be biased because of incomplete reporting, it seems unlikely that those tested by the 
RTA would have a systematic difference in the probability of having a laboratory report 
collected by the eHARS system. Likewise, some persons without documentation of receipt 
of posttest counseling and referral may have in fact received their results. These incomplete 
data would only affect comparison sites and would argue for considering the model with 
only receipt of RTA and not receipt of posttest counseling and referral (Table 3, model 2) as 
our primary model because it does not include this potentially biased covariate. Both LA and 
San Francisco allow for anonymous HIV testing at several of their HIV test sites. Those 
Delaney et al. Page 8













testing anonymously could neither be linked to surveillance data nor actively referred for 
HIV care because a name must be associated with the test result for these activities to occur. 
Using the RTA with clients who test anonymously might provide an additional opportunity 
to discuss switching to confidential testing to facilitate immediate referral.60
Recent CDC guidance for HIV testing program managers includes instructions for use of 
multiple rapid tests in nonclinical settings,61 and the recently revised surveillance case 
definition for HIV infection allows for reporting of HIV cases to the CDC’s National HIV 
Surveillance System based on reactive results on 2 different rapid tests.62 Both jurisdictions 
participating in this study have continued to use RTA since the study ended, although they 
now use an algorithm that includes 2 finger stick rapid tests.23,24 Other jurisdictions have 
also implemented RTA and found it to be cost saving compared with requiring laboratory 
confirmation of all preliminary-positive rapid test results.20,21 Use of RTA involves some 
additional logistical complexities; these implementation challenges are discussed in detail 
elsewhere.23,24 However, this study demonstrated the benefits of an improved PPV and 
immediate referral to HIV care without opportunity for loss during follow-up. These 
advantages, coupled with other interventions designed to improve linkage to HIV care and 
treatment, make implementation of RTA an appealing addition to the complement of 
strategies for HIV testing and linkage to care in nonclinical settings in the United States.
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The diagram presents the sample size for each part of the analysis. Of 59,299 individuals 
tested, only 1165 had a preliminary-positive rapid test, including 161 false positive and 1004 
results confirmed by the laboratory testing algorithm. Of 1004 persons eligible for analyses 
of time to care and linkage to care, 181 tested anonymously, and therefore, no information to 
allow for matching to the HIV case reporting system was available. An additional 48 
individuals were determined to be cases who resided outside San Francisco or LA County 
Health Department’s jurisdiction for the purposes of tracking ongoing laboratory reporting. 
This left a total of 775 individuals who could be included in the linkage to care analysis, but 
most of these were not tested with the rapid test algorithm.
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A, Kaplan–Meier failure time curves representing the estimated time from diagnosis to first 
laboratory evidence of HIV care (defined as the first HIV-1 VL result reported in the HIV 
surveillance registry), stratified by whether a client tested at an intervention or comparison 
site. Intervention sites included 9 sites in LA and San Francisco, CA, that offered a rapid test 
algorithm (RTA) and same-day referral to HIV care to persons who tested positive by RTA. 
Comparison sites offered the standard rapid testing protocol for the United States, a single 
rapid test, which, if reactive, would require laboratory-based confirmation. Standard HIV 
rapid testing sites provided posttest counseling and referral after the confirmatory test results 
were available from the laboratory, on average 8 days after the initial HIV rapid test. 
Although clients tested at intervention sites had a slightly shorter time to laboratory evidence 
of care, this difference did not reach statistical significance, P = 0.4551, log rank test 
(assuming no difference between the 2 curves). B, The same Kaplan–Meier failure time 
curve for intervention sites, but here those testing positive at comparison sites were further 
divided based on whether they returned for their test results. Clients who received their test 
results and referral because they returned for confirmatory results at a comparison site and 
clients who received a result by testing at an intervention site had a very similar distribution 
of time to laboratory evidence of HIV care, although the initial difference between 
immediate referral and delayed referral based on the need to wait for a laboratory result is 
apparent up through day 20 after the positive rapid test result. Those who received a result 
and a referral (whether at intervention or comparison sites) had a significantly shorter time 
from HIV test result to HIV care compared with those who did not come back to receive 
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their laboratory-based confirmatory results and therefore did not receive a referral to HIV 
care, P < 0.001, log rank test (assuming no difference between the curves).
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TABLE 1
Demographic Characteristics of Clients Tested in LA and San Francisco Publically Funded HCT Sites, August 
2007–March 2009
Total Intervention Sites (n = 9) Comparison Sites (n = 23)
n % n % n %
Characteristic 59,299 100.0 17,386 100.0 41,913 100.0
Project area
 LA 42,108 71.0 10,243 58.9 31,865 76.0
 SF 17,191 29.0 7143 41.1 10,048 24.0
Risk group
 MSM 25,474 43.0 9878 56.8 15,596 37.2
 IDU 3577 6.0 607 3.5 2970 7.1
 Other 30,248 51.0 6901 39.7 23,347 55.7
Race/ethnicity
 White 20,839 35.1 7067 40.7 13,772 32.9
 Black 10,819 18.2 2709 15.6 8110 19.4
 Hispanic 19,555 33.0 4180 24.0 15,375 36.7
 Other 8086 13.6 3430 19.7 4656 11.1
Homeless 3340 5.6 804 4.6 2536 6.1
Anonymous tests 14,768 24.9 4510 25.9 10,258 24.5
Previously tested 45,163 76.2 14,437 83.0 30,726 73.3
 Known positive 224 0.4 22 0.1 202 0.5
 Did not get most recent result 729 1.2 140 0.8 589 1.4
IDU, Injection drug user; SF, city of San Francisco.
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TABLE 2
HIV Test Results and Time to Receipt of Confirmed Results and Referral Among Clients With Preliminary-
Positive Rapid Test Results in LA and San Francisco, CA, August 2007–March 2009
Intervention Sites Comparison Sites
n % n %
Total tested 17,386 100.0 41,913 100.0
Positive on first rapid 250 1.40 915 2.20
False positive on first rapid test* 37 14.8 124 13.6
Positive by RTA 213 NA
Confirmed positive* 213 85.2 791 86.4
PPV† 100 86.4
Received results 250 100.0 430 47.0
Days between initial and




Denominator for percentage is those with a positive result on the first rapid test.
†
For intervention sites, the PPV reported is that of the rapid test algorithm, compared with laboratory-based confirmatory testing. For comparison 
sites, the PPV is of the single initial rapid test, again compared with laboratory-based confirmatory testing.
‡
The intervention included same-day referral for all persons with a positive rapid test algorithm result.
NA, not applicable because the RTA was not performed in Comparison sites.
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